U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06939296) titled 'A Research Study of VCT220 in Adult Chinese Participants With Obesity' on April 10.
Brief Summary: The main purpose of this study is to assess how VCT220 tablets affect the bodyweight in obese or overweight adult participants. Participant will be randomly assigned to the high-dose group, low-dose group, or placebo group. Each participant will take the study drug orally once daily for 12 months.
Study Start Date: Dec. 24, 2024
Study Type: INTERVENTIONAL
Condition:
Obesity
Overweight
Intervention:
DRUG: VCT220
A small molecule GLP-1R drug, film coated tablet
DRUG: Placebo
Placebo tablets
Recruitment Status: ACTIVE_NOT_RECRU...